Results 11 to 20 of about 70,790 (271)

Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry

Arthritis Research & Therapy, 2020
Background At present, etanercept represents the most commonly prescribed biologic agent for juvenile idiopathic arthritis (JIA) treatment. Children and adolescents with JIA are often treated with etanercept over long periods, sometimes even into ...
Giulia Armaroli, Ariane Klein, Gerd Ganser, Michael J. Ruehlmann, Frank Dressler, Anton Hospach, Kirsten Minden, Ralf Trauzeddel, Ivan Foeldvari, Jasmin Kuemmerle-Deschner, Frank Weller-Heinemann, Andreas Urban, Gerd Horneff   +12 more
doaj   +2 more sources

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy

Experimental Hematology & Oncology, 2021
Cytokine release syndrome (CRS) is the most common toxicity induced by chimeric antigen receptor (CAR) T cell therapy. At present, anti-IL-6 agents including tocilizumab and siltuximab have been applied in the treatment of CRS.
Lina Zhang, Shuai Wang, Ji Xu, Run Zhang, Han Zhu, Yujie Wu, Liying Zhu, Jianyong Li, Lijuan Chen   +8 more
doaj   +2 more sources

Targeting anti-inflammatory treatment can ameliorate injury-induced neuropathic pain. [PDF]

PLoS ONE, 2013
Tumor necrosis factor-α plays important roles in immune system development, immune response regulation, and T-cell-mediated tissue injury. The present study assessed the net value of anti-tumor necrosis factor-α treatment in terms of functional recovery ...
Katsuyuki Iwatsuki, Tetsuya Arai, Hideyuki Ota, Shuichi Kato, Tadahiro Natsume, Shigeru Kurimoto, Michiro Yamamoto, Hitoshi Hirata   +7 more
doaj   +1 more source

Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept

Annals of the Rheumatic Diseases, 2020
The novel coronavirus (severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), responsible for the coronavirus disease 2019 (COVID-19)) outbreak is a major public health concern worldwide, while it is spreading globally. It is not yet known whether
P. Duret, Eden Sebbag, Auriane Mallick, S. Gravier, L. Spielmann, L. Messer   +5 more
semanticscholar   +1 more source

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission

Arthritis & Rheumatology, 2020
Patients with rheumatoid arthritis (RA) in whom remission is achieved following combination therapy with methotrexate plus etanercept face an ongoing medication burden.
J. Curtis, P. Emery, E. Karis, B. Haraoui, V. Bykerk, P. Yen, G. Kricorian, J. Chung   +7 more
semanticscholar   +1 more source

Comparison of the inhibitory effect of tocilizumab and etanercept on the progression of joint erosion in rheumatoid arthritis treatment

Scientific Reports, 2022
We compared the efficacy of tocilizumab and etanercept in inhibiting radiographic progression of joint destruction in rheumatoid arthritis. Overall, 187 patients treated with etanercept or tocilizumab were selected.
Shinya Hayashi, Tsukasa Matsubara, Toshihisa Maeda, Koji Fukuda, Keiko Funahashi, Marowa Hashimoto, Ken Tsumiyama, Tomoyuki Kamenaga, Yoshinori Takashima, Tomoyuki Matsumoto, Shotaro Tachibana, Ryosuke Kuroda   +11 more
doaj   +1 more source

Etanercept alleviates psoriasis by reducing the Th17/Treg ratio and promoting M2 polarization of macrophages

Immunity, Inflammation and Disease, 2022
Introduction This study aimed to investigate the effect of etanercept in psoriasis and its underlying mechanism. Methods Female mice were treated with imiquimod (IMQ) to induce psoriasis, and intraperitoneally administered etanercept (0.1–0.4 mg/ml). The
Xiaoqing Li, Ming Jiang, Xia Chen, Weiguo Sun   +3 more
doaj   +1 more source

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial

Arthritis & Rheumatology, 2019
To examine the efficacy of methotrexate monotherapy relative to etanercept monotherapy and the value of combining methotrexate and etanercept for the treatment of patients with psoriatic arthritis (PsA).
P. Mease, D. Gladman, D. Collier, C. Ritchlin, P. Helliwell, L. Liu, G. Kricorian, J. Chung   +7 more
semanticscholar   +1 more source

Intra-articular vs. systemic administration of etanercept in antigen-induced arthritis in the temporomandibular point. Part I: histological effects

Pediatric Rheumatology Online Journal, 2009
Background Temporomandibular joint (TMJ) arthritis in children causes alterations in craniomandibular growth. This abnormal growth may be prevented by an early anti-inflammatory intervention.
Nyengaard Jens R, Pedersen Thomas K, Küseler Annelise, Stoustrup Peter, Kristensen Kasper D, Hauge Ellen, Herlin Troels   +6 more
doaj   +1 more source

Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial

Arthritis & Rheumatology, 2019
To assess the risk of major adverse cardiovascular events (MACE) in patients with rheumatoid arthritis (RA) treated with tocilizumab compared to those treated with the tumor necrosis factor inhibitor etanercept.
J. Giles, N. Sattar, S. Gabriel, P. Ridker, S. Gay, Charles Warne, D. Musselman, L. Brockwell, Emma Shittu, M. Klearman, T. Fleming   +10 more
semanticscholar   +1 more source